Option chain shows key data for Atossa Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Atossa Therapeutics.

Atossa Therapeutics (NASDAQ:ATOS) Stock, Option Chain

ATOSSA THERAPEUTICS INC

Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Redcliffe,,Queensland,,Australia,-,May,14,2018:,Domino's,Pizza,Store

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ATOS

KRYS

PLAY

SUPN

Domino&#39;s Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday

Screenshot 2024-04-01 at 9.57.34 PM

Biotech

General

This Biotech Works On All Phases Of Breast Cancer, From Prevention To Post Surgery

This Drug Developer Is Dedicated To “Transforming The Breast Cancer Paradigm”

Penny Stocks

Interview

Dr. Steven Quay MD, PhD, President &amp; CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga.

This Drug Developer Is Dedicated To &#34;Transforming The Breast Cancer Paradigm&#34;

Atossa Therapeutics Inc

Atos SE

ATOS ORIGIN SA U/ADR NEW by Atos Origin SA

Atos SE DR

Press Releases

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Legal

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Health Care

Management

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Earnings

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Alector

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

C4 Therapeutics

Coherus BioSciences

Coya Therapeutics

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Immunic

Inozyme Pharma

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lyell Immunopharma

Macrogenics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

RAPT Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Vigil Neuroscience

Vaxart

Exagen

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Ascendiant Capital

HC Wainwright & Co.

Atossa Genetics

Comments

Atossa Therapeutics

Atossa Therapeutics (ATOS) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell